Stakeholders Divided On How HHS-FDA Relations Will Shake Out

As the Biden transition team starts pinpointing potential health agency picks , FDA watchers are divided on whether the agency is on a path to facing less or more oversight from HHS. While some stakeholders expect a Biden FDA will try to buck any remnants of the HHS micromanagement instilled by the Trump administration, a consumer advocate says a pro-consumer HHS pick could lead the department to more closely oversee FDA in order to ensure its policies are not tilted...